



2025
Corporate Sustainability
and Social Impact Report
Data and Disclosures Appendix



Jazz Pharmaceuticals.

Data and Disclosures Appendix

This document is a companion to Jazz Pharmaceuticals' 2025 Corporate Sustainability and Social Impact (CSSI) Report and should be referenced in conjunction with it. It contains performance data, reporting framework disclosures and supporting reference material for the period January 1, 2025, through December 31, 2025, unless otherwise noted.

For questions about this document or the 2025 CSSI Report, contact corporateaffairsmediainfo@jazzpharma.com.

In this section:

Performance Indicators	2
Our Stakeholders	3
The United Nations Sustainable Development Goals (SDGs)	4
Task Force on Climate-related Financial Disclosures (TCFD)	5
Sustainability Accounting Standards Board (SASB) Index	9
Global Reporting Initiative (GRI) Index	13
Forward-Looking Statements	19



Performance Indicators

PATIENT PERFORMANCE INDICATORS	2025	2024
Overall		
Countries served by our medicines	~100	~100
Medicines marketed	9	9
Research & Development		
R&D spend	16% of revenue ¹	20% of revenue ¹
R&D programs	>35	>35
R&D employees	>740	>740
Patient Centricity		
Patient & caregiver engagements	1,843	863

PEOPLE PERFORMANCE INDICATORS	2025	2024
Workforce Composition		
Total employees worldwide	~2,900	~2,800
Employees — U.S.	1,544	1,458
Employees — Europe & International Markets ²	424	429
Employees — Ireland ²	217	200
Employees — U.K. ²	705	716
Leadership Composition		
Executive Committee — total members	11	9
VP and above — total	79	82
Employee Engagement		
Employee survey participation rate	84%	84%
Employees who feel Jazz cares about health & wellbeing (% favorable)	91%	84%
Employees who feel Jazz provides flexibility (% favorable)	92%	89%
Inclusion & Belonging		
Percent of employees active in ConcERTos & Affinity Forums	38%	37%
Required gender pay gap reports published (countries)	3	3
Occupational Health & Safety		
Fatalities due to work-related injuries	0	0
High-consequence work-related injuries	0	0
Total recordable incidents, number / rate (TRIR) ³	1 / 0.04	2 / 0.08
Lost Time Incidents, number / rate (LTIR) ³	1 / 0.04	2 / 0.08
Near miss frequency rate (NMFR)	3.86	4.03

GOVERNANCE PERFORMANCE INDICATORS	2025	2024
Board Composition		
Total directors	13	12
Percent independent directors	85%	92%
Board tenure – 0 to 3 years	4	2
Board tenure – 3 to 7 years	2	3
Board tenure – 7+ years	7	7
Residency – North America (U.S.)	9	8
Residency – Europe (Ireland)	3	3
Residency – Asia (Hong Kong)	1	1

COMMUNITY PERFORMANCE INDICATORS	2025	2024
Charitable Giving		
Organizations supported	77	75
Total charitable contributions (\$ million)	4.5	3.9

ENVIRONMENTAL PERFORMANCE INDICATORS	2025	2024 ⁵
Greenhouse Gas (GHG) Emissions⁴		
Total Scope 1 emissions (tCO ₂ e)	4,758	-
Total Scope 2 emissions – market-based (tCO ₂ e)	2,818	-
Total Scope 2 emissions – location-based (tCO ₂ e)	4,361	-
Energy & Renewables		
Percent of internal manufacturing sites fully operating on renewable electricity / sites	100% / 3	67% / 2
Internal manufacturing sites with EV charging points	3	3
Total non-renewable electricity (kilowatt-hour, kWh)	4,835,662	-
Total renewable electricity (kWh)	11,487,843	-
Total thermal energy (including purchased heat, natural gas, and other fuels) (kWh)	11,011,917	-
Renewable / low-emission fuel and fleet mix		
Hybrid Electric Vehicle (HEV)	55.4%	-
Internal Combustion Engine (ICE)	31.6%	-
Plug-in Hybrid Electric Vehicle (PHEV)	11.8%	-
Battery Electric Vehicle (BEV)	1.2%	-

Environmental Management Systems	2025	2024
Sites certified to ISO 14001:2015	3	1
Sites certified to ISO 45001 (Occupational Health and Safety Management Systems)	3	1
My Green Lab certification program (labs)	7	1

1. Non-GAAP adjusted R&D spend as reported in the 2025 YE results. 2. Europe excludes U.K. and Ireland. 3. per 200,000 working hours. 4. Jazz continues to develop and refine its GHG inventory, including the assessment of organizational boundaries and the classification of activities across emissions scopes. Scope 3 emissions data remains under evaluation in 2026. As this work progresses, previously reported figures, baselines and scope classifications may be clarified, and targets adjusted, consistent with the GHG Protocol's recalculation guidance. Any such adjustments will be reflected in future reporting. 5. Where 2024 data are not available, cells are left blank.

Our Stakeholders

By engaging our global stakeholders consistently and substantively, we stay anchored to what matters and can identify where Jazz can create the greatest impact. Jazz engages with the following key stakeholder groups:

STAKEHOLDER GROUP	ENGAGEMENT CHANNELS	SELECT OUTCOMES OF ENGAGEMENT
Patients and caregivers	Engage directly with patients, caregivers and patient organizations to understand lived experiences and unmet needs, gathering input through patient engagement programs, partnerships and clinical trial interactions.	Informed clinical trial design, patient-facing materials and how therapies are developed and delivered to better reflect patient needs.
Employees	Engage employees through leadership communication, listening exercises and ongoing feedback mechanisms to understand priorities and experiences.	Shaped our wellness programs, employee policies and workplace practices to strengthen culture, engagement and alignment with business objectives.
Investors	Maintain regular dialogue with investors through meetings on strategy, performance and governance with executive leadership and Board members.	Informed discussions regarding long-term value creation, strategic capital allocation and governance policies.
Governments, public officials and regulators	Engage with regulatory bodies and public stakeholders to ensure compliance and contribute to policy discussions relevant to our business and patients.	Informed approaches to access, innovation, patient-centered policy and legal requirements, including sustainability reporting, in multiple jurisdictions.
Customers	Engage healthcare providers through commercial and medical affairs teams to support clinical education and appropriate patient identification. Partner with payers and pharmacy benefit managers to support formulary access, reimbursement and patient services.	Strengthened formulary positioning and prescriber engagement, supporting therapy adoption and patient support programs that reduce access barriers for rare disease patients.
Suppliers	Partner with suppliers to ensure supply chain resiliency and uphold ethical and safety standards through ongoing engagement and defined expectations.	Informed supply chain practices including code of conduct and operational reliability.
Partners and peers	Collaborate with external partners, including nonprofit organizations, academic institutions and industry peers, to share expertise and advance initiatives aligned with our rare disease focus.	Informed development of partnerships supporting patient access, community engagement and targeted impact initiatives.
Industry associations	Participate in industry groups and associations to share expertise, contribute to collective initiatives and stay informed on emerging trends and standards.	Contributed to industry dialogue on topics such as access, innovation and responsible practices, informing company positions and alignment with evolving standards.
Communities	Engage with local communities where our people live and work through employee volunteering programs, charitable giving and partnerships with organizations aligned with our rare disease mission.	Shaped the grants, donations, sponsorships and non-commercial partnerships we invested in and strengthened our presence in communities where we operate.
Our Board	Oversees corporate strategy, performance and risk management, with standing committees providing focused oversight across key domains. For CSSI specifically, the NCGC oversees sustainability strategy and practices and the Audit Committee oversees sustainability reporting and compliance with applicable disclosure requirements.	Informed CSSI program development, governance structures and disclosure practices, with sustainability, commitments integrated into broader Board oversight of corporate strategy, risk, people programs and product innovation.


The United Nations Sustainable Development Goals

Since 2022, Jazz has aligned its CSSI program with seven United Nations Sustainable Development Goals (SDGs) most relevant to our business and stakeholders: SDG 3 (Good Health and Well-Being), SDG 5 (Gender Equality), SDG 8 (Decent Work and Economic Growth), SDG 10 (Reduced Inequalities), SDG 12 (Responsible Consumption and Production), SDG 13 (Climate Action) and SDG 16 (Peace, Justice and Strong Institutions). These goals align with our efforts across our four impact pillars—Patients, People, Community and Planet—and provide a consistent, internationally recognized reference point as we set objectives, assess progress and report on our impacts.



3 – Good Health and Well-Being

We support SDG 3 by developing and providing life-changing medicines for patients with serious diseases and by working to broaden access, support and education across our therapeutic areas.



8 – Decent Work and Economic Growth

We contribute to SDG 8 by offering high-quality jobs, competitive total rewards and opportunities for continuous learning, enabling our people to build meaningful careers while supporting sustainable business performance.



13 – Climate Action

We support SDG 13 through ongoing work to measure and reduce our emissions, increase our use of renewable electricity and develop and apply data-driven plans to guide decarbonization of our operations over time.



5 & 10 – Gender Equality and Reduced Inequalities

We support SDGs 5 and 10 by seeking inclusive leadership, applying equal employment opportunity considerations in our people practices and engaging with partners to address health and opportunity gaps in the communities we serve.



12 – Responsible Consumption and Production

We advance SDG 12 by strengthening our environmental and operational management systems, improving resource efficiency and working with suppliers to encourage responsible practices across our value chain.



16 – Peace, Justice and Strong Institutions

We contribute to SDG 16 by maintaining strong governance, enterprise risk management and ethics and compliance frameworks and by engaging with partners and institutions to help improve access to safe, high-quality care.

Task Force on Climate-related Financial Disclosures

The disclosures herein follow the structure and recommended topics of the TCFD framework.

Governance

A) Describe the Board’s oversight of climate-related risks and opportunities.

B) Describe management’s role in assessing and managing climate-related risks and opportunities.

Jazz recognizes that climate-related risks and opportunities may be relevant to strategic decision-making and long-term value creation. As such, we continue to evaluate the appropriate governance mechanisms to reflect these considerations, where appropriate, in our business planning and oversight.


BOARD OVERSIGHT

The Board oversees our CSSI program for addressing significant sustainability-related risks and opportunities, including climate-related considerations that may impact our business and stakeholders. In addition to its role in reviewing our approach to corporate governance, the Nominating and Corporate Governance Committee (NCGC) has oversight responsibilities for CSSI program activities and practices. The NCGC periodically reviews and discusses with management our practices with respect to sustainability matters that are expected to have a significant impact on Jazz’s performance, business activities or reputation. The Audit Committee has oversight of Jazz’s sustainability disclosure strategy and compliance with applicable disclosure requirements.

MANAGEMENT OVERSIGHT

Our Chief Executive Officer (CEO), Chief Legal Officer (CLO) and Chief Financial Officer (CFO) provide managerial oversight and direction relative to the scope and implementation of the CSSI program. The Executive Committee (EC) Sponsors maintain day-to-day responsibility for CSSI implementation through cross-functional working groups that coordinate enterprise risk, compliance, sustainability and reporting activities. These structures serve as the foundation for expanding climate-specific governance and reporting in the future.

CSSI Governance Structure



NCGC periodically reviews and discusses sustainability matters expected to have a significant impact on Jazz’s business performance or reputation.

Audit Committee oversees Jazz’s sustainability disclosure practices and compliance with applicable disclosure requirements.

Executive Management (CEO, CLO and CFO) provide joint managerial oversight and direction for the CSSI program.

EC Sponsors are accountable for developing and prioritizing CSSI goals, approving projects and ensuring objectives are embedded within their respective business functions.

The **CSSI Program Team** leads CSSI program development and execution, coordinating cross-functional engagement, annual reporting and communications across all pillars.

CSSI Pillar Leaders oversee pillar-specific programs and targets, verify reporting accuracy and serve as the primary link between technical teams and executive leadership.

The **Sustainability Reporting Team** manages data validation, assurance and non-financial reporting to ensure the integrity of all CSSI disclosures.

CSSI Technical Teams serve as subject matter experts, accountable for delivering accurate, traceable and well-governed data in support of CSSI reporting and initiative execution.

Strategy




- A) Describe the climate-related risks and opportunities the organization has identified over the short, medium and long term.**
- B) Describe the impact of climate-related risks and opportunities on the organization's businesses, strategy and financial planning.**
- C) Describe the resilience of the organization's strategy, taking into consideration different climate-related scenarios including a 2°C or lower scenario.**

Building on our European Sustainability Reporting Standards (ESRS)-aligned double materiality assessment and gap analysis completed in 2024, Jazz expanded its evaluation of climate-related financial risks and opportunities through climate scenario analysis used to test the resilience of the company under various global temperature rise conditions of 1.5°C and 4°C. This work resulted in the identification of the following climate-related risks and opportunities (CROs), which were prioritized for incorporation into our CSSI program.

The CROs discussed in this report are not necessarily material to Jazz for purposes of the U.S. federal securities laws, under any other statute or regulation or otherwise, and their discussion herein should not be construed as a determination of materiality by Jazz. These also may not be the only CROs applicable to Jazz. Jazz will continue to monitor climate-related risks and opportunities and assess where resilience planning may be appropriate.

Jazz may at any time, without notice, modify or discontinue any of the initiatives discussed in this report.








Climate-Related Risk

RISK TYPE	LINK TO JAZZ	TIME HORIZON*	POTENTIAL IMPACT	MANAGEMENT APPROACH
Transition Risks: Reputation Policy and Legal	Evolving climate policy and regulatory compliance ¹	  	Evolving climate and sustainability-related regulations, including emissions reduction and disclosure requirements, may raise compliance costs and accelerate pressure to decarbonize operations and supply chains.	As the global regulatory landscape regarding corporate sustainability reporting evolves, we continue to monitor and prepare for new regulations that may impact Jazz. This has driven advancements in our reporting mechanisms to meet climate policy and regulatory requirements, including the E.U. Corporate Sustainability Reporting Directive (CSRD) and California Climate Corporate Data Accountability Act (SB 253) and Climate-Related Financial Risk Act (SB 261). Our preparations also benefit our voluntary sustainability reporting and Enterprise Risk Management (ERM) processes. In parallel, our operations continue to implement efficiency and conservation measures that reduce our climate impact.
Physical Risks: Acute	Operational disruption and asset risk ²	  	Extreme weather events (e.g. storms, flooding) may cause physical damage or prolonged disruption at key operational and manufacturing facilities—both within our company and across our broader value chain.	<p>We assess weather-related risks at our facilities and evaluate reinforcements, where needed, to improve resilience in collaboration with our insurance company. As part of this, we have response plans in place at our sites for weather-related risks.</p> <p>In addition, we are in the process of developing a global business continuity plan in the event of catastrophic loss of assets and production facilities, including those that may be caused by a climate-related event.</p>

*Time horizon from which risks could likely begin to have an impact:  Short (2030),  Medium (2040),  Long (2050).

1. Evolving climate policy and regulatory compliance is an amalgamation of three individual transition risk CROs: Policy / regulatory non-compliance (Reputation); Climate regulation / carbon pricing to deliver government policy targets (Policy and Legal); and Variation in regulatory market signals (Policy and Legal). 2. Operational disruption and asset risk is an amalgamation of two physical risk CROs: Extreme weather operational and asset risk (Acute); and Supply chain disruption (Acute).

Climate-Related Opportunity

OPPORTUNITY	LINK TO JAZZ	TIME HORIZON*	POTENTIAL IMPACT	MANAGEMENT APPROACH
Energy Source Resource Efficiency	Low Carbon Energy and Operational Efficiency ¹	 	Investments in energy efficiency and renewable energy may lower operating costs over time, support long-term cost stability and enhance the competitiveness of Jazz's internal manufacturing operations.	<p>Jazz continues to integrate sustainability practices across our internal manufacturing operations to drive meaningful progress and enhance business resilience.</p> <p>In 2025, Jazz implemented 15 priority energy and infrastructure projects across its manufacturing network, focused on reducing energy demand and improving site performance. These initiatives included LED lighting expansions, insulation upgrades and electrification of hot water systems.</p> <p>Jazz also continued to advance its transition to renewable electricity across its operations. All three of Jazz's internal manufacturing sites and one corporate office now operate on 100% renewable electricity. Electric vehicle charging infrastructure at the three internal manufacturing locations is powered entirely by renewable sources. These steps reduce reliance on higher-carbon energy sources while supporting long-term cost stability and operational resilience.</p>
Products and Services	Climate-Resilient and Sustainable Supply Chain ²	  	Embedding climate resilience and sustainability criteria into supplier selection and procurement processes may strengthen supply chain performance, support continuity of critical inputs and improve Jazz's ability to meet evolving regulatory and stakeholder expectations.	<p>Jazz is broadening its sustainability efforts beyond direct operations, with a focus on materials, supply chain emissions and the long-term availability of critical inputs, working to strengthen value chain resilience and support more sustainable delivery of medicines to patients.</p> <p>In 2025, Jazz started Scope 3 screening and supplier segmentation to better understand emissions across its value chain. Based on this analysis, Jazz initiated a collaborative pilot with 10 suppliers to evaluate practical and mutually beneficial approaches to support future decarbonization efforts and strengthen Jazz's supply chain positioning over time.</p>
Products and Services	Demand for Sustainable Products and R&D Innovation ³	 	Shifts in buyer preferences toward more sustainably-produced products could increase demand for sustainable drug discovery, development and manufacturing.	<p>We continue to evaluate opportunities across our value chain and in our product development and manufacturing processes to reduce energy consumption, minimize waste generation and improve resource efficiency.</p> <p>In 2025, Jazz initiated work to transition to peat-free cultivation for Epidiolex® (cannabidiol).</p> <p>Jazz also established a transition plan to expand the use of validated alternative testing methods, including recombinant approaches where scientifically appropriate and regulatorily accepted. Over time, this transition is expected to reduce reliance on natural resource-based inputs and support more sustainable value chain practices.</p>

*Time horizon from which risks could likely begin to have an impact:  Short (2030),  Medium (2040),  Long (2050).

1. Low Carbon and Operational Efficiency is an amalgamation of five individual opportunity CROs: Energy efficiency and self-generation (Energy Source); Low carbon footprint (Energy Source); Decentralized energy generation (Energy Source); Policy support and new technology (Energy Source); and Enhanced environmental performance (Resource Efficiency). 2. Climate-Resilient and Sustainable Supply Chain is an amalgamation of two individual resource efficiency and resilience CROs: Sustainable procurement (Products and Services); and Supply chain / resource diversification (Products and Services). 3. Demand for Sustainable Products and R&D Innovation is an amalgamation of two individual opportunity CROs: R&D activities (Products and Services); and Shifting consumer preferences (Products and Services).

Risk Management

- A) Describe the organization's processes for identifying and assessing climate-related risks.**
- B) Describe the organization's processes for managing climate-related risks.**
- C) Describe how processes for identifying, assessing and managing climate-related risks are integrated into the organization's overall risk management.**

We recognize that risks, including climate-related risks, are an inherent part of conducting business in today's environment. Our ERM framework is a comprehensive approach designed to identify, assess, prepare for and mitigate risks that may affect Jazz.

Our NCGC governs our ERM process with oversight from our EC. Top risks and their mitigating activities are reported to the EC, NCGC and ultimately owned and reviewed by the full Board of Directors. We believe our proactive and collaborative approach to ERM allows us not only to safeguard our business but also to contribute positively to our stakeholders, communities and the environment in which we operate.

In 2025, Jazz conducted a climate-related risk assessment. The process began by understanding how CROs may influence our current and future business strategy. This included reviewing how CROs are identified, evaluated and managed within our existing ERM framework. We also considered how emerging regulatory risks are integrated into this framework. An initial long list of CROs was developed based on internal analysis and scenario-based insights. The list was categorized into transition risks, physical risks and opportunities.

Senior stakeholders then participated in a qualitative scenario analysis to evaluate the potential business impacts of these CROs under two global warming pathways: 1.5°C and 4°C. This process informed the development of a short list of priority CROs. We further evaluated the qualitative and potential financial implications of these priority CROs through impact pathway mapping and heat mapping across our value chain to assess their significance.

In addition to our climate-specific risk assessment, our ERM team facilitates semi-annual discussions with business functions to review updates to previously identified risks, surface new or emerging risks and evaluate changes to risk mitigation activities. Risk owners—including the designated CSSI leader responsible for CSSI implementation and related risk assessments—are accountable for identifying and submitting risk considerations through this process.

While climate-related risks have been evaluated in alignment with our CRO assessment process, they have not, to date, been classified as significant risks within our ERM framework. We continue to monitor evolving regulatory and physical risk drivers that may impact business exposure and risk thresholds.

1. Jazz continues to develop and refine its GHG inventory, including the assessment of organizational boundaries and the classification of activities across emissions scopes. Scope 3 emissions data remains under evaluation in 2026. As this work progresses, previously reported figures, baselines and scope classifications may be clarified, and targets adjusted, consistent with the GHG Protocol's recalculation guidance. Any such adjustments will be reflected in future reporting.

Metrics and Targets

- A) Disclose the metrics used by the organization to assess climate-related risks and opportunities in line with its strategy and risk management process.**
- B) Disclose Scope 1, Scope 2, and if appropriate, Scope 3 greenhouse gas (GHG) emissions and the related risks.**
- C) Describe the targets used by the organization to manage climate-related risks and opportunities and performance against targets.**

In 2025, we completed an in-depth, data-driven assessment of our environmental footprint to understand where our emissions sit across our operations. Gross greenhouse gas (GHG) emissions were calculated in accordance with the GHG Protocol Corporate Standard, using an operational control boundary.

Scope 1 and 2 Emissions in 2025 were¹:

- Scope 1: 4,758 tCO₂e
- Scope 2 (location-based): 4,361 tCO₂e; (market-based): 2,818 tCO₂e

Scope 3 emissions data is not yet available, though we are in the process of mapping selected Scope 3 categories to understand where our emissions are concentrated.

To manage CROs, Jazz monitors a defined set of metrics integrated into ERM and business planning processes. These include:

- Absolute Scope 1 and Scope 2 GHG emissions
- Total renewable and non-renewable electricity (kWh)
- Key operational indicators tied to emissions reduction actions (e.g., efficiency gains)

These metrics inform target-setting, capital allocation, operational planning and ongoing monitoring of CROs.

Building on this foundation, we established a target to reduce absolute Scope 1 and 2 GHG emissions by 35% by 2030, using 2025 as our baseline year. This target is underpinned by enhanced governance, data and integration between sustainability and core business functions built out over 2025. It also reflects a shift from foundational work to more structured execution.

Progress against this target will be measured annually. As 2025 represents the baseline year, performance tracking will commence in 2026. To support delivery of this target, in 2025 we developed a decarbonization plan that outlines what we believe is a credible pathway for emissions reduction. The plan is anchored in a defined set of operational actions, including energy efficiency upgrades, equipment electrification, fuel switching, resource optimization and renewable electricity procurement, and is designed to guide capital allocation and operational decision-making as the business evolves.

We view this decarbonization plan not only as an environmental commitment, but as a strategic driver of value for the business. It supports more efficient operations, helps manage costs and strengthens the long-term resilience and performance of our infrastructure as we scale.

Sustainability Accounting Standards Board Index

The SASB Index reflects the metrics included within the SASB Standard for the Biotechnology & Pharmaceuticals industry, as well as select metrics from the Agricultural Products industry standard, with data available at the time of publication relating to our fiscal year (unless otherwise noted), which ended December 31, 2025. For the disclosures that we do not currently report, we are either evaluating our internal reporting processes to determine the feasibility of future disclosures, or we have deemed that they are not relevant or applicable to our business operations at this time.

SASB TOPIC	CODE	ACCOUNTING METRIC	2025 DATA
Agricultural Products Industry Standard			
Greenhouse Gas Emissions	FB-AG-110a.1	Gross global Scope 1 emissions	Jazz's Scope 1 emissions in 2025 were 4,758 tCO ₂ e. ¹
	FB-AG-110a.2	Long-term and short-term strategy/plan to manage Scope 1 emissions, emissions reduction targets, and analysis of performance against those targets	See the "Planet" section under "Building a Foundation for Resilient Growth" in the 2025 Corporate Sustainability and Social Impact Report and the "TCFD" and the "Performance Indicators" sections of this appendix.
	FB-AG-110a.3	Fleet fuel consumed; percentage renewable	See the "Planet" section under "Building a Foundation for Resilient Growth" in the 2025 Corporate Sustainability and Social Impact Report and the "TCFD" and the "Performance Indicators" sections of this appendix.
Energy Management	FB-AG-130a.1	(1) Operational energy consumed; (2) percentage grid electricity and (3) percentage renewable	See the "Planet" section under "Building a Foundation for Resilient Growth" in the 2025 Corporate Sustainability and Social Impact Report and the "TCFD" and the "Performance Indicators" sections of this appendix.
Water Management	FB-AG-140a.1	(1) Total water withdrawn; (2) total water consumed; percentage of each in regions with High or Extremely High Baseline Water Stress	See the "Planet" section under "Increasing Energy Efficiency and Site Performance" in the 2025 Corporate Sustainability and Social Impact Report and the "Performance Indicators" section of this appendix.
	FB-AG-140a.2	Description of water management risks and discussion of strategies and practices to mitigate those risks	See the "Planet" section under "Increasing Energy Efficiency and Site Performance" in the 2025 Corporate Sustainability and Social Impact Report and the "TCFD" section of this appendix.
	FB-AG-140a.3	Number of incidents of non-compliance associated with water quality permits, standards and regulations	We track environmental incidents in our internal EHS platform, and we did not have any non-compliance with water permits, standards or regulations.
Workforce Health And Safety	FB-AG-320a.1	(1) Total recordable incident rate (TRIR); (2) fatality rate; and (3) near miss frequency rate (NMFR) for (a) direct employees and (b) contract employees	See the "People" section under "Occupational Health and Safety" in the 2025 Corporate Sustainability and Social Impact Report and the "Performance Indicators" section of this appendix.
Ingredient Sourcing	FB-AG-440a.1	Identification of principal crops and risks/opportunities presented by climate change	See the "TCFD" section of this appendix.

1. Jazz continues to develop and refine its GHG inventory, including the assessment of organizational boundaries and the classification of activities across emissions scopes. Scope 3 emissions data remains under evaluation in 2026. As this work progresses, previously reported figures, baselines and scope classifications may be clarified, and targets adjusted, consistent with the GHG Protocol's recalculation guidance. Any such adjustments will be reflected in future reporting.

SASB TOPIC	CODE	ACCOUNTING METRIC	2025 DATA
Biotechnology And Pharmaceutical Industry Standard			
Safety Of Clinical Trial Participants	HC-BP-210a.1	Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	See the "Governance" section under "Patient Safety and Product Quality" in the 2025 Corporate Sustainability and Social Impact Report.
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	Jazz does not comment on confidential legal matters.
Access To Medicines	HC-BP-240a.1	Description of actions/initiatives to promote access to health care products for priority diseases and in priority countries as defined by Access to Medicine Index	See the "Patients" section under "Increasing Access and Affordability" in the 2025 Corporate Sustainability and Social Impact Report.
	HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	No Jazz products are on the list at the time of reporting.
Affordability And Pricing	HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	Jazz does not comment on confidential legal matters.
	HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across product portfolio compared to previous year	Jazz does not report this due to the risk of potentially revealing competitively sensitive information.
	HC-BP-240b.3	Percentage change in (1) list price and (2) net price of product with largest increase compared to previous year	Jazz does not report this due to the risk of potentially revealing competitively sensitive information.
Drug Safety	HC-BP-250a.1	Products listed in public medical product safety or adverse event alert databases	Available via the FDA Adverse Reporting Website .
	HC-BP-250a.2	Number of fatalities associated with products	Available via the FDA Adverse Reporting Website .
	HC-BP-250a.3	(1) Number of recalls issued, (2) total units recalled	Jazz had zero (0) recalls issued.
	HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	Jazz does not currently operate a product takeback or reuse program.
	HC-BP-250a.5	Number of enforcement actions taken in response to violations of Good Manufacturing Practices (GMP) or equivalent standards, by type	Jazz does not comment on confidential legal matters.

SASB TOPIC	CODE	ACCOUNTING METRIC	2025 DATA	
Biotechnology And Pharmaceutical Industry Standard (Cont.)	Counterfeit Drugs	HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	<p>Jazz Pharmaceuticals takes the trust that patients put in us to deliver safe medicines very seriously. Our manufacturing is subject to a high level of control and documentation throughout the manufacturing process, from the procurement of raw materials to the release of the finished product. We carefully manage our supply chain through strict policies and procedures designed to keep the drug distribution safe and secure. We maintain a continuous internal audit program and a biennial corporate audit program, which are overseen by local authorities.</p> <p>In some markets, we distribute our medicines ourselves, but in other markets, including the U.S., we use third-party distributors. In all cases in which we use service providers, we enter into quality and technical agreements with them to protect the integrity of the process.</p> <p>In both Europe and the U.S., our medicines are packaged and labeled with individual serial numbers, making them much easier to track and making counterfeits easier to identify. Serialized numbering allows identification to be checked throughout the supply chain. If a serial number scan is not valid, it triggers an alert and initiates an investigation to verify whether the medicine in question is a legitimate Jazz product.</p> <p>See the "Governance" section under "Brand Protection" in the 2025 Corporate Sustainability and Social Impact Report.</p>
		HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks with counterfeit products	<p>If our alert and investigation systems determine that a particular product may be counterfeit or falsified, we have defined procedures in place designed to alert our customers, business partners and regulatory authorities. Our procedures require us to perform and document root cause investigations and corrective and preventive actions.</p> <p>See the "Governance" section under "Brand Protection" in the 2025 Corporate Sustainability and Social Impact Report.</p>
		HC-BP-260a.3	Number of actions that led to raids, seizure, arrests and/or filing of criminal charges related to counterfeit products	Jazz does not comment on confidential legal matters.
Ethical Marketing		HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Jazz does not comment on confidential legal matters.
		HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	See our Code of Conduct and Ethics .
Employee Recruitment, Development And Retention		HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development staff	See the "People" section under "Building Capabilities and Developing Our People" in the 2025 Corporate Sustainability and Social Impact Report.
		HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals and (d) all others	See the "People" section under "Building Capabilities and Developing Our People" in the 2025 Corporate Sustainability and Social Impact Report.

SASB TOPIC	CODE	ACCOUNTING METRIC	2025 DATA
Biotechnology And Pharmaceutical Industry Standard (Cont.)			
Supply Chain Management	HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier 1 suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	<p>Jazz does not participate in the Rx-360 International Pharmaceutical Supply Chain Consortium's audit program but has engaged an independent third party to conduct an end-to-end supply chain and brand protection audit.</p> <p>We adhere to the GMP and Good Distribution Practice (GDP) standards set by the FDA and other health authorities. We operate in compliance with all applicable rules and regulations. All third parties with whom we do business are expected to operate in compliance with all applicable laws and regulations of the countries, states and localities in which they operate.</p> <p>The standards, expectations and contractual agreements that we have with third parties are consistent with the standards we set for ourselves as reflected in our Code of Conduct and Ethics.</p>
	HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Jazz does not comment on confidential legal matters.
	HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	See our Code of Conduct and Ethics .
	HC-BP-000.B	Number of drugs in portfolio and in R&D (Phases 1-3)	See Our Medicines .

Global Reporting Initiative Index

Statement of use: Jazz Pharmaceuticals plc has reported in reference to the GRI Standards when practicable for the period of January 1, 2025, through December 31, 2025. GRI 1 used: GRI 1: Foundation 2021.

GRI STANDARD	RESPONSE
GRI 2: General Disclosures	
2-1 Organizational details	Jazz Pharmaceuticals plc, a public limited company formed under the laws of Ireland, is headquartered on the Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.
2-2 Entities included in the organization's sustainability reporting	Jazz Pharmaceuticals plc and all its consolidated subsidiaries (unless otherwise noted).
2-3 Reporting period, frequency and contact point	This Jazz Pharmaceuticals plc CSSI report is for Jan. 1, 2025, through Dec. 31, 2025, unless otherwise stated. For questions about this document or the 2025 CSSI Report, contact corporateaffairsmediainfo@jazzpharma.com .
2-4 Restatements of information	Not applicable.
2-5 External assurance	In 2025, KPMG provided limited assurance over our Scope 1 and 2 GHG emissions. KPMG is independent of Jazz Pharmaceuticals. The assurance statement is available on the last page of the 2025 Corporate Sustainability and Social Impact Report.
2-6 Activities, value chain and other business relationships	See the "Planet" section under "Expanding Focus to Production and Our Value Chain", the "Governance" section under "Maintaining Ethics and Responsible Business Practices" in the 2025 Corporate Sustainability and Social Impact Report.
	See the "TCFD" section of this appendix.
	See Jazz Pharmaceuticals Form 10-K , Proxy Statement and jazzpharma.com .
2-7 Employees	See the "People" section in the 2025 Corporate Sustainability and Social Impact Report.
2-8 Workers who are not employees	See the "Planet" section under "Expanding Focus to Production and Our Value Chain" in the 2025 Corporate Sustainability and Social Impact Report.
2-9 Governance structure and composition	See the "Governance" section in the 2025 Corporate Sustainability and Social Impact Report.
	See the "TCFD" section of this appendix.
	See Jazz Pharmaceuticals Form 10-K , Proxy Statement and jazzpharma.com .
2-10 Nomination and selection of the highest governance body	See Jazz Pharmaceuticals Form 10-K , Proxy Statement and jazzpharma.com .
2-11 Chair of the highest governance body	See Jazz Pharmaceuticals Form 10-K .

GRI STANDARD	RESPONSE
GRI 2: General Disclosures (Cont.)	
2-12 Role of the highest governance body in overseeing the management of impacts	<p>See the “Governance” section in the 2025 Corporate Sustainability and Social Impact Report.</p> <p>See the “TCFD” section of this appendix.</p> <p>See Jazz Pharmaceuticals Form 10-K.</p>
2-13 Delegation of responsibility for managing impacts	<p>See the “Governance” section in the 2025 Corporate Sustainability and Social Impact Report.</p> <p>See the “TCFD” section of this appendix.</p> <p>See Jazz Pharmaceuticals Form 10-K and Proxy Statement.</p>
2-14 Role of the highest governance body in sustainability reporting	<p>See the “Governance” section in the 2025 Corporate Sustainability and Social Impact Report.</p> <p>See GRI 2-12 and 2-13.</p> <p>See the “TCFD” section of this appendix.</p>
2-15 Conflicts of interest	<p>See Jazz Pharmaceuticals Form 10-K.</p>
2-16 Communication of critical concerns	<p>Jazz has multiple communication channels, including an ethics hotline and internal reporting mechanisms, to escalate critical concerns to leadership and the Board.</p> <p>See the “Governance” section under “Maintaining Ethics and Responsible Business Practices” section in the 2025 Corporate Sustainability and Social Impact Report.</p>
2-17 Collective knowledge of the highest governance body	<p>See the “Governance” section in the 2025 Corporate Sustainability and Social Impact Report.</p>
2-18 Evaluation of the performance of the highest governance body	<p>See Jazz Pharmaceuticals Form 10-K.</p>
2-19 Remuneration policies	<p>See Jazz Pharmaceuticals Form 10-K.</p>
2-20 Process to determine remuneration	<p>See Jazz Pharmaceuticals Form 10-K.</p>
2-21 Annual total compensation ratio	<p>See Jazz Pharmaceuticals Form 10-K.</p>
2-22 Statement on sustainable development strategy	<p>See the 2025 Corporate Sustainability and Social Impact Report.</p>
2-23 Policy commitments	<p>See the “Governance” section under “Maintaining Ethics and Responsible Business Practices” section in the 2025 Corporate Sustainability and Social Impact Report.</p>
2-24 Embedding policy commitments	<p>See the “Governance” section under “Maintaining Ethics and Responsible Business Practices” section in the 2025 Corporate Sustainability and Social Impact Report.</p>
2-25 Processes to remediate negative impacts	<p>See the “Governance” section under “Maintaining Ethics and Responsible Business Practices” section in the 2025 Corporate Sustainability and Social Impact Report.</p>

GRI STANDARD	RESPONSE
GRI 2: General Disclosures (Cont.)	
2-26 Mechanisms for seeking advice and raising concerns	See the “Governance” section under “Maintaining Ethics and Responsible Business Practices” section in the 2025 Corporate Sustainability and Social Impact Report.
2-27 Compliance with laws and regulations	Our management team and our Board of Directors are committed to honesty and compliance with all laws, rules, regulations and corporate policies that apply to our business, and we expect the same commitment from our employees, consultants, business partners and service providers.
2-28 Membership Associations	Jazz is a member of several industry associations including Biotechnology Innovation Organization (BIO) and European Federation of Pharmaceutical Industries and Associations (EFPIA).
2-29 Approach to stakeholder engagement	See the “Our Stakeholders” section of this appendix.
GRI 3: Material Topics 2024	
3-1 Process to determine material topics	See GRI 201-2.
	See the “TCFD” section of this appendix.
3-2 List of material topics	See the “TCFD” and “SASB” sections of this appendix.
3-3 Management of material topics	See GRI 2-12 and 2-13.
	See the “TCFD” section of this appendix.
GRI 201 Economic Performance 2016	
201-2 Financial implications and other risks and opportunities due to climate change	<p>At the close of 2024, we completed a double materiality assessment (DMA) conducted in alignment with the then ESRS methodology as part of our preparation for CSRD compliance. The DMA provided a structured, evidence-based view of Jazz’s most significant impacts, risks and opportunities across our operations, workforce, supply chain and the patients we serve. Beginning in 2025, we shared the findings more broadly across the organization to build shared understanding of these impacts, risks and opportunities, strengthen cross-functional alignment on where to focus efforts and resources and move those insights from evaluation to application, shaping the priorities reflected in the pillar sections that follow. We anticipate updating the DMA in the context of our refreshed corporate strategy.</p> <p>In addition, in 2025, Jazz expanded its evaluation of CROs through climate scenario analysis used to test the resilience of the company under various global temperature rise conditions of 1.5°C and 4°C. This work resulted in the identification of CROs outlined in the “TCFD” section of this appendix.</p> <p>The CROs discussed are not necessarily material to Jazz for purposes of the U.S. federal securities laws, under any other statute or regulation or otherwise, and their discussion herein should not be construed as a determination of materiality by Jazz. These also may not be the only CROs applicable to Jazz. Jazz will continue to monitor climate-related risks and opportunities and assess where resilience planning may be appropriate.</p>

GRI STANDARD	RESPONSE
GRI 305: Emissions 2016	
305-1 Direct (Scope 1) GHG emissions	<p>Jazz's Scope 1 emissions in 2025 were 4,758 tCO₂e.¹</p> <p>See the "Planet" section under "Building a Foundation for Resilient Growth" in the 2025 Corporate Sustainability and Social Impact Report.</p> <p>See the "TCFD" and "Performance Indicators" sections of this appendix.</p>
305-2 Energy indirect (Scope 2) GHG emissions	<p>Jazz's Scope 2 (location-based) emissions in 2025 were 4,361 tCO₂e; Jazz's Scope 2 (market-based) emissions in 2025 were 2,818 tCO₂e.¹</p> <p>See the "Planet" section under "Building a Foundation for Resilient Growth" in the 2025 Corporate Sustainability and Social Impact Report.</p> <p>See the "TCFD" and "Performance Indicators" sections of this appendix.</p>
305-3 Other indirect (Scope 3) GHG emissions	<p>Jazz's Scope 3 emissions data is not yet available, though we are in the process of mapping selected Scope 3 categories to understand where our emissions are concentrated.</p> <p>See the "TCFD" section of this appendix.</p>
305-5 Reduction of GHG emissions	<p>Because 2025 represents our baseline year for GHG emissions, we do not report quantified reductions against this baseline under 305-5; the full impact of our initiatives will be reflected in performance comparisons beginning in 2026.</p> <p>In 2025, Jazz initiated the implementation of a centralized monitoring platform integrating electricity, fossil fuels, and fugitive and process emissions data across internal manufacturing sites, with water use and thermal energy planned for full integration in 2026.</p> <p>Jazz moved from early-stage assessment to more structured readiness and implementation of its environmental reporting and governance processes. We made meaningful progress in aligning our disclosures and internal data structures with evolving regulatory expectations. We also advanced governance and controls around environmental data and reporting, with initial steps to integrate these requirements into core business processes.</p> <p>See the "Planet" section under "Building a Foundation for Resilient Growth" in the 2025 Corporate Sustainability and Social Impact Report and "Performance Indicators" section in this appendix.</p> <p>See the "TCFD" section of this appendix.</p>

1. Jazz continues to develop and refine its GHG inventory, including the assessment of organizational boundaries and the classification of activities across emissions scopes. Scope 3 emissions data remains under evaluation in 2026. As this work progresses, previously reported figures, baselines and scope classifications may be clarified, and targets adjusted, consistent with the GHG Protocol's recalculation guidance. Any such adjustments will be reflected in future reporting.

GRI STANDARD	RESPONSE
GRI 403: Occupational Health And Safety 2018	
403-1 Occupational health and safety management system	<p>We seek to maintain a safe and healthy work environment through comprehensive risk assessment of our processes and operations, effective workplace design and the implementation of appropriate control measures. These include engineering controls, prescriptive procedures, work instructions and the use of personal protective equipment. We adopt extended training and induction programs for our personnel. We operate in compliance with relevant national and international health and safety standards.</p> <p>Each of our manufacturing and operational sites operate under a defined Environmental, Health, Safety and Security (EHSS) management system. These systems apply to all employees, contractors and others who may be affected by our operations. Health and safety performance is monitored monthly using a centralized, cloud-based EHSS platform. Our health and safety systems are structured to meet the requirements of the European Union Framework Directive on Safety and Health at Work and to align with the International Organization for Standardization (ISO) Section 6.4.6 of ISO 26000 (Labor Practices — Health and Safety at Work) and are certified with ISO 45001 for occupational health and safety.</p> <p>See the “People” section under “Occupational Health and Safety” in the 2025 Corporate Sustainability and Social Impact Report.</p>
403-2 Hazard identification, risk assessment, and incident investigation	See the “People” section under “Occupational Health and Safety” in the 2025 Corporate Sustainability and Social Impact Report.
403-3 Occupational health services	See the “People” section under “Occupational Health and Safety” in the 2025 Corporate Sustainability and Social Impact Report.
403-4 Worker participation, consultation, and communication on occupational health and safety	See the “People” section under “Occupational Health and Safety” in the 2025 Corporate Sustainability and Social Impact Report.
403-5 Worker training on occupational health and safety	See the “People” section under “Occupational Health and Safety” in the 2025 Corporate Sustainability and Social Impact Report.
403-6 Promotion of worker health	See the “People” section under “Investing in Employee Wellbeing” and “Occupational Health and Safety” in the 2025 Corporate Sustainability and Social Impact Report.
403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	See the “People” section under “Occupational Health and Safety” in the 2025 Corporate Sustainability and Social Impact Report.
403-8 Workers covered by an occupational health and safety management system	See the “People” section under “Occupational Health and Safety” in the 2025 Corporate Sustainability and Social Impact Report.
403-9 Work-related injuries	<p>See the “People” section under “Occupational Health and Safety” in the 2025 Corporate Sustainability and Social Impact Report.</p> <p>See the “Performance Indicators” in this appendix.</p>
GRI 405: Diversity And Equal Opportunity 2016	
405-1 Diversity of governance bodies and employees	<p>See the “People” section under “Fostering Inclusion and Engagement” and in the “Governance” section in the 2025 Corporate Sustainability and Social Impact Report.</p> <p>In addition, Jazz holds events throughout the year to celebrate key dates and foster connection and education. In 2025, this included International Women’s Day, Black History Month in the U.K. and U.S., Asian American and Pacific Islander (AAPI) Heritage Month, Hispanic Heritage Month, Pride, Juneteenth, Indigenous Peoples Month and Global Diversity Month.</p>

Abbreviations

ABBREVIATION	DEFINITION
1LM	First-Line Maintenance
2L	Second-Line
3Rs	Replace, Reduce, Refine
AAPI	Asian American and Pacific Islander
ADOD	All Dimensions of Diversity ConcERTo
AI	Artificial Intelligence
ANDA	Abbreviated New Drug Application
BC	Breast Cancer
BEV	Battery Electric Vehicle
BIO	Biotechnology Innovation Organization
BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase
BREEAM	Building Research Establishment Environmental Assessment Method
BTC	Biliary Tract Cancer
CDO	Chief Digital Officer
CECO	Chief Ethics and Compliance Officer
CEO	Chief Executive Officer
CFO	Chief Financial Officer
CISO	Chief Information Security Officer
CLO	Chief Legal Officer
CO₂	Carbon Dioxide
ConcERTos	Employee Resource Teams
CROs	Climate-related Risks and Opportunities
CSRD	Corporate Sustainability Reporting Directive
CSSI	Corporate Sustainability and Social Impact
DMA	Double Materiality Assessment
DMG	Diffuse Midline Glioma
EAP	Early Access Program
EC	Executive Committee
EFPIA	European Federation of Pharmaceutical Industries and Associations
EHSS	Environmental, Health, Safety and Security
EIP	Employee Equity Incentive Plans
EMA	European Medicines Agency

ABBREVIATION	DEFINITION
ERM	Enterprise Risk Management
ERTs	Employee Resources Teams
ES-SCLC	Extensive-Stage Small Cell Lung Cancer
ESRS	European Sustainability Reporting Standards
E.U.	European Union
FCPA	Foreign Corrupt Practices Act
FDA	U.S. Food and Drug Administration
GCP	Good Clinical Practice
GDP	Good Distribution Practice
GEA	Gastroesophageal Adenocarcinoma
GHG	Greenhouse Gas
GLP	Good Laboratory Practice
GMOs	Genetically Modified Organisms
GMP	Good Manufacturing Practice
GRI	Global Reporting Initiative
HBA	Healthcare Businesswomen's Association
HEV	Hybrid Electric Vehicle
HOLA	Hispanic Organization for Leadership Advancement
ICE	Internal Combustion Engine
ICH	International Council for Harmonisation
ISO	International Organization for Standardization
JAWS	Jazz Association of Women Supporters
JUNO	Jazz Upskilling and Networking in Oncology
KSP	Kent Science Park
kWh	Kilowatt-hour
LED	Light-Emitting Diode
LLM	Large Language Model
LSC	Life Science Cares
LTIR	Lost Time Incident Rate
m³	Cubic Meter
NCGC	Nominating and Corporate Governance Committee
NCS	Non-Commercial Supply
NMFR	Near Miss Frequency Rate
NPS	Named Patient Supply

ABBREVIATION	DEFINITION
OS	Overall Survival
PCAC	Patient Centricity Advisory Council
PCPG	Advanced Pheochromocytoma and Paraganglioma
PCSC	Patient Centricity Steering Committee
PDUFA	Prescription Drug User Fee Act
PHEV	Plug-in Hybrid Electric Vehicle
PQP	Prequalification of Medicines Programme
PSP / PSUs	Performance Vesting Restricted Stock Unit Awards
R&D	Research and Development
RAF	Rapidly Accelerated Fibrosarcoma
RAS	Rat Sarcoma
SASB	Sustainability Accounting Standards Board
sBLA	supplemental Biologics License Application
SCLC	Small Cell Lung Cancer
SDGs	United Nations Sustainable Development Goals
t	Ton (metric ton/metric tonne)
TCFD	Task Force on Climate-related Financial Disclosures
tCO_{2e}	Metric Tons Of Carbon Dioxide Equivalent
TRIR	Total Recordable Incident Rate
U.S.	United States
U.K.	United Kingdom
UKBA	U.K. Bribery Act
VP	Vice President



Forward-Looking Statements

This report contains forward-looking statements, which may include, but are not limited to, CROs and future CSSI programs, efforts, initiatives, goals and benefits, including with respect to the operation of our manufacturing facilities, the goals of our environmental policies and management systems, and our commitment to advancing our CSSI programs and reporting of our sustainability metrics. These forward-looking statements are based on our current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of significant risks and uncertainties, which include, without limitation, risks and uncertainties associated with: our ability to appropriately allocate capital and other resources; litigation, tax and legal compliance

risk and costs, especially if materially different from the amount we expect to incur or have accrued for, and any disruptions caused by the same; and changes in the legal and regulatory environment, including environmental, health and safety laws and regulations. Risks and uncertainties of which we are not currently aware may also affect our forward-looking statements and may cause actual results and timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the publication date of this statement or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by us on our website or otherwise. We undertake no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in our expectations or other circumstances that exist after the date as of which the forward-looking statements were made.